弥漫性大 B 细胞淋巴瘤的新策略：将基因表达分析的研究结果转化到临床实践中。
New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice.
机构信息
University of Rochester Medical Center, Rochester, New York 14642, USA.
出版信息
Clin Cancer Res. 2011 Oct 1;17(19):6112-7. doi: 10.1158/1078-0432.CCR-11-1073. Epub 2011 Aug 15.
Abstract
Gene expression profiling has had a major impact on our understanding of the biology and heterogeneity of diffuse large B-cell lymphoma (DLBCL). Using this technology, investigators can identify biologic subgroups of DLBCL that provide unique targets for rational therapeutic intervention. This review summarizes these potential targets and updates the progress of clinical development of exciting novel agents for the treatment of DLBCL. Results of ongoing studies suggest that in the near future, we will be able to use gene expression profiling, or an accurate surrogate, to define the best therapeutic approach for individual patients with DLBCL.
摘要
基因表达谱分析对我们理解弥漫性大 B 细胞淋巴瘤（DLBCL）的生物学和异质性产生了重大影响。利用这项技术，研究人员可以鉴定出 DLBCL 的生物学亚群，为合理的治疗干预提供独特的靶点。这篇综述总结了这些潜在的靶点，并更新了治疗 DLBCL 的新型药物的临床开发进展。正在进行的研究结果表明，在不久的将来，我们将能够使用基因表达谱分析或准确的替代物来为每个 DLBCL 患者定义最佳的治疗方法。
相似文献
1
New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice.弥漫性大 B 细胞淋巴瘤的新策略：将基因表达分析的研究结果转化到临床实践中。
Clin Cancer Res. 2011 Oct 1;17(19):6112-7. doi: 10.1158/1078-0432.CCR-11-1073. Epub 2011 Aug 15.
2
Lipid metabolism-related gene signature predicts prognosis and unveils novel anti-tumor drugs in specific type of diffuse large B cell lymphoma.脂质代谢相关基因特征可预测预后，并揭示特定类型弥漫性大 B 细胞淋巴瘤的新型抗肿瘤药物。
Mol Med. 2024 Nov 13;30(1):210. doi: 10.1186/s10020-024-00988-4.
3
Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma.迈向弥漫性大 B 细胞淋巴瘤新的分子分类学。
Cancer Discov. 2020 Sep;10(9):1267-1281. doi: 10.1158/2159-8290.CD-20-0174. Epub 2020 Jul 2.
4
The significance of FOXP1 in diffuse large B-cell lymphoma.FOXP1在弥漫性大B细胞淋巴瘤中的意义。
Leuk Lymphoma. 2017 May;58(5):1037-1051. doi: 10.1080/10428194.2016.1228932. Epub 2016 Sep 27.
5
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.复发/难治性弥漫性大B细胞淋巴瘤中用于个性化精准医学的新型药物靶点：综述
Mol Cancer. 2015 Dec 11;14:207. doi: 10.1186/s12943-015-0474-2.
6
Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?我们是否应该在治疗弥漫性大B细胞淋巴瘤中使用起源细胞和双蛋白表达？
Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):91-97. doi: 10.1016/j.clml.2017.12.003. Epub 2017 Dec 24.
7
ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?ABC型、GCB型及双打击弥漫性大B细胞淋巴瘤：亚型在治疗选择上有差异吗？
Am Soc Clin Oncol Educ Book. 2015:e449-57. doi: 10.14694/EdBook_AM.2015.35.e449.
8
[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].[弥漫性大B细胞淋巴瘤：基于临床和生物学异质性的治疗进展]
Rinsho Ketsueki. 2015 Oct;56(10):2047-55. doi: 10.11406/rinketsu.56.2047.
9
Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.弥漫性大 B 细胞淋巴瘤：预后标志物及其对治疗的影响。
Expert Rev Hematol. 2016 May;9(5):471-7. doi: 10.1586/17474086.2016.1146584. Epub 2016 Feb 19.
10
How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.基因多态性如何影响弥漫性大B细胞淋巴瘤患者接受R-CHOP治疗后的临床反应和毒性。
Blood Rev. 2017 Jul;31(4):235-249. doi: 10.1016/j.blre.2017.02.005. Epub 2017 Feb 27.
引用本文的文献
1
Prognostic value of red blood cell distribution width and D-Dimer in diffuse large B-cell lymphoma: Systematic review and meta-analysis.红细胞分布宽度和D-二聚体在弥漫性大B细胞淋巴瘤中的预后价值：系统评价和荟萃分析
Cancer Rep (Hoboken). 2024 Jan;7(1):e1936. doi: 10.1002/cnr2.1936. Epub 2023 Nov 24.
2
Clinical significance of circulating neutrophils and lymphocyte subsets in newly diagnosed patients with diffuse large B-cell lymphoma.初诊弥漫大 B 细胞淋巴瘤患者循环中性粒细胞和淋巴细胞亚群的临床意义。
Clin Exp Med. 2023 Jul;23(3):815-822. doi: 10.1007/s10238-022-00867-4. Epub 2022 Aug 8.
3
Expression and Prognostic Value of Glucose Transporter 3 in Diffuse Large B Cell Lymphoma.葡萄糖转运蛋白3在弥漫性大B细胞淋巴瘤中的表达及预后价值
Onco Targets Ther. 2022 Feb 25;15:181-191. doi: 10.2147/OTT.S338826. eCollection 2022.
4
Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965.用AZD3965抑制单羧酸转运蛋白-1后追踪营养物质通量
Cancers (Basel). 2020 Jun 26;12(6):1703. doi: 10.3390/cancers12061703.
5
Protein-protein interaction modulators: advances, successes and remaining challenges.蛋白质-蛋白质相互作用调节剂：进展、成果与尚存挑战
Biophys Rev. 2019 Aug;11(4):559-581. doi: 10.1007/s12551-019-00570-x. Epub 2019 Jul 12.
6
Prognostic Value of D-Dimer in Patients with Diffuse Large B-cell Lymphoma: A Retrospective Study.弥漫性大 B 细胞淋巴瘤患者 D-二聚体的预后价值：一项回顾性研究。
Curr Med Sci. 2019 Apr;39(2):222-227. doi: 10.1007/s11596-019-2023-5. Epub 2019 Apr 23.
7
The expression level of hsa-miR-146a-5p in plasma-derived exosomes of patients with diffuse large B-cell lymphoma.弥漫性大B细胞淋巴瘤患者血浆来源外泌体中hsa-miR-146a-5p的表达水平。
J Res Med Sci. 2019 Feb 25;24:10. doi: 10.4103/jrms.JRMS_507_18. eCollection 2019.
8
MicroRNAs as Biomarkers of B-cell Lymphoma.微小RNA作为B细胞淋巴瘤的生物标志物
Biomark Insights. 2018 Oct 16;13:1177271918806840. doi: 10.1177/1177271918806840. eCollection 2018.
9
Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis.中性粒细胞与淋巴细胞比值在弥漫性大B细胞淋巴瘤患者中的预后作用：一项更新的剂量反应荟萃分析
Cancer Cell Int. 2018 Aug 22;18:119. doi: 10.1186/s12935-018-0609-9. eCollection 2018.
10
Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study.弥漫性大B细胞淋巴瘤患者中贫血与较差预后相关：一项单中心回顾性研究。
Turk J Haematol. 2018 Aug 3;35(3):181-184. doi: 10.4274/tjh.2017.0437. Epub 2018 Mar 28.
本文引用的文献
1
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515.一项新诊断的弥漫性大 B 细胞非霍奇金淋巴瘤患者接受标准剂量环磷酰胺、多柔比星、长春新碱、泼尼松（CHOP）和利妥昔单抗联合贝伐珠单抗治疗的 2 期临床试验：SWOG0515。
Blood. 2012 Aug 9;120(6):1210-7. doi: 10.1182/blood-2012-04-423079. Epub 2012 Jun 25.
2
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.来那度胺可与 R-CHOP（R2CHOP）在侵袭性 B 细胞淋巴瘤的初始化疗中安全联合使用：I 期研究。
Leukemia. 2011 Dec;25(12):1877-81. doi: 10.1038/leu.2011.165. Epub 2011 Jul 1.
3
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.非生发中心 B 细胞样弥漫大 B 细胞淋巴瘤对来那度胺的反应高于生发中心 B 细胞样表型。
Cancer. 2011 Nov 15;117(22):5058-66. doi: 10.1002/cncr.26135. Epub 2011 Apr 14.
4
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.MHC 类 II 转录激活物 CIITA 是淋巴癌中经常发生的基因融合伙伴。
Nature. 2011 Mar 17;471(7338):377-81. doi: 10.1038/nature09754. Epub 2011 Mar 2.
5
Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.使用福尔马林固定、石蜡包埋组织的核酸酶保护检测，准确地将弥漫性大 B 细胞淋巴瘤分类为生发中心 B 细胞和活化 B 细胞亚型。
Clin Cancer Res. 2011 Jun 1;17(11):3727-32. doi: 10.1158/1078-0432.CCR-10-2573. Epub 2011 Mar 1.
6
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.硼替佐米联合 CHOP-利妥昔单抗方案治疗初治弥漫性大 B 细胞淋巴瘤和套细胞淋巴瘤。
J Clin Oncol. 2011 Feb 20;29(6):690-7. doi: 10.1200/JCO.2010.31.1142. Epub 2010 Dec 28.
7
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.治疗类风湿关节炎的一种口服脾脏酪氨酸激酶（Syk）抑制剂。
N Engl J Med. 2010 Sep 30;363(14):1303-12. doi: 10.1056/NEJMoa1000500. Epub 2010 Sep 22.
8
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.硼替佐米联合 R-CHOP 方案治疗初治侵袭性非霍奇金淋巴瘤的Ⅰ期临床试验。
Cancer. 2010 Dec 1;116(23):5432-9. doi: 10.1002/cncr.25509. Epub 2010 Jul 27.
9
Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial.硼替佐米在 2 期 PINNACLE 试验中治疗套细胞淋巴瘤的潜在生物标志物。
Leuk Lymphoma. 2010 Jul;51(7):1269-77. doi: 10.3109/10428194.2010.483302.
10
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.LNH-98.5 试验患者的长期预后，这是第一项比较利妥昔单抗-CHOP 与 DLBCL 患者标准 CHOP 化疗的随机研究：成人淋巴瘤研究组的一项研究。
Blood. 2010 Sep 23;116(12):2040-5. doi: 10.1182/blood-2010-03-276246. Epub 2010 Jun 14.
Zotero 插件